# US 2011/0301233 A1 · Novel Polyisoprenylated Benzophenone Derivatives from Garcinia paucinervis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301233 A1
- Document ID: US20110301233A1
- Status: Published application
- Kind: A1
- Application number: 12/793,691
- Filed: 2010-06-04
- Published: 2011-12-08
- Earliest claimed: 2010-06-04
- Inventors: XUE-MEI GAO; Ting Yu; Kathy Qian Luo; Hong Xi Xu
- Web page: https://patentgrep.com/patent/US20110301233A1

## CPC

- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61P 35/00: Antineoplastic agents
- C07D 307/77: ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D 307/94: spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Novel polyisoprenylated benzophenone derivatives isolated from the plant Garcinia paucinervis. Among these new compounds, paucinones A-C (Compounds 1-3) contains an unexpected cyclohexane-spiro-tetrahydrofuran moiety. A 1-methylene-3,3-dimethylcyclohexane group never reported before was found in the structure of paucinone D (Compound 4). Structures of these compounds were elucidated with spectroscopic evidence. The relative stereochemistry of 1-4 was determined by NOESY correlations. These compounds a potent ability to activate caspase-3 in HeLa-C3 cells within 72 hours at a low concentration and significant cytotoxicity against HeLa-C3 cells.

## Claims

### Claim 1

A compound, having a structural as follows:
wherein R10 is —C═CCH3CH3 or
and R11 is —H and R12 is —CH2OH, or R11 and R12 together with the carbon atom to which they attached form the group of:
wherein R1 is independently —H, —OH or Me-32 and R2 is —OH or Me-32.

### Claim 2 (depends on 1)

The compound according to claim 1, which is Paucinone A, wherein R10 is —C═CCH3CH3 and R11 and R12 together with the carbon atom to which they attached form the group of:
wherein R, is Me-32 and R2 is —OH.

### Claim 3 (depends on 1)

The compound according to claim 1, which is Paucinone B, wherein R10 is —C═CCH3CH3 and R11 and R12 together with the carbon atom to which they attached form the group of:
wherein R2 is Me-32 and R, is —OH.

### Claim 4 (depends on 1)

The compound according to claim 1, which is Paucinone C, wherein R10 is —C═CCH3CH3 and R11, and R12 together with the carbon atom to which they attached form the group of:
wherein R, is —H and R2 is —OH.

### Claim 5 (depends on 1)

The compound according to claim 1, which is Paucinone D, wherein R11 is —H,
R12 is —CH2OH, R10 is

### Claim 6 (depends on 1)

A method of inducing apoptosis in tumor cells, comprising a step of administering to a mammalian subject having tumor cells a therapeutically effective amount of a compound of claim 1.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said mammalian subject is a human patient suffering from cancer.

### Claim 8 (depends on 1)

A pharmacological composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The pharmacological composition according to claim 8, wherein the pharmacological composition is formulated in a dosage form selected from a group consisting of tablet, capsule, and injection.
